Salivary Melatonin Profile: What This Test Actually Measures

What a Salivary Melatonin Profile Actually Tests

A salivary melatonin profile does not return a single number the way a fasting glucose test does. It returns a time-series curve. Saliva samples are collected every 30 to 60 minutes across the evening, typically starting 5 to 6 hours before habitual bedtime and continuing until roughly 30 minutes after usual sleep onset. Each sample is analyzed by enzyme-linked immunosorbent assay (ELISA) or mass spectrometry for melatonin concentration in pg/mL. The resulting curve tells a clinician not just how much melatonin the pineal gland secretes, but when secretion starts and whether that timing matches reported sleep patterns.

Why Saliva Rather Than Blood or Urine

Salivary melatonin tracks free (unbound) plasma melatonin, at roughly one-quarter to one-third of plasma concentration. A widely cited methods review has discussed this saliva-plasma relationship and supports saliva as a valid proxy for circadian phase assessment. Published estimates of how closely salivary DLMO tracks plasma DLMO in minutes vary by study and protocol; a reviewing clinician should treat any single precise figure for that agreement as something to confirm against the specific validation study being cited, not as a fixed constant.

Saliva collection is non-invasive, avoids the light exposure and stress of venipuncture, and can be completed at home with a temperature-controlled kit. Urinary 6-sulfatoxymelatonin (aMT6s) reflects the prior night's total melatonin output but cannot pinpoint DLMO timing. Serum sampling requires a clinic stay under controlled low-light conditions, which adds cost and logistics. Saliva is the most practical outpatient biofluid for circadian phase testing.

The DLMO Calculation

Labs compute DLMO using one of two methods. The fixed-threshold method sets DLMO at the first of at least two consecutive samples exceeding 3 pg/mL (or 4 pg/mL in some commercial protocols). The mean-based method sets DLMO at the first sample exceeding the mean of the lowest daytime samples plus two standard deviations. The Endocrine Society's 2015 Clinical Practice Guideline on melatonin treatment of circadian rhythm sleep-wake disorders describes DLMO as the standard circadian phase marker used in clinical and research settings and discusses the fixed-threshold approach. Both calculation methods are used in practice; knowing which one a given lab applies matters when comparing results over time.

Normal Ranges: What the Numbers Mean

A "normal" result on this test answers three separate questions: is the DLMO time appropriate for the reported sleep schedule, is the peak concentration in a typical range, and does the curve rise the way a healthy pineal gland's output usually rises?

DLMO Timing

In adults with a conventional sleep schedule (bedtime near 23:00), DLMO typically occurs between roughly 21:00 and 22:30. A study of healthy adults under standardized dim-light conditions found a mean DLMO around 21:44, generally 1.5 to 2.5 hours before habitual sleep onset.

A DLMO notably earlier than 19:30 suggests an advanced circadian phase; a DLMO notably later than 23:30 suggests a delayed phase. Both can be clinically meaningful even when someone reports "normal" total sleep duration, because a mismatch between internal circadian phase and social or work schedule is what drives the fragmented sleep and daytime impairment in these disorders.

Peak Melatonin Concentration

Peak salivary melatonin in healthy adults aged 20 to 40 typically falls between about 80 and 120 pg/mL, usually reached between 02:00 and 04:00 in the dark. Values tend to decline with age. Some studies have documented an age-related decline in nocturnal melatonin amplitude in older adults compared with younger adults. Adults over 65 commonly show lower peaks than younger adults; the exact magnitude varies across studies and labs, so results in older adults should be read against an age-appropriate reference range rather than the young-adult range.

Peak values under roughly 20 pg/mL are generally considered low-amplitude and can reflect light exposure during sleep, certain medications, or reduced pineal output, discussed below.

Rate of Rise

A melatonin curve that rises from near-baseline to peak over a few hours is typical of an intact circadian signal. A curve that rises very slowly, or that never clearly separates from baseline, suggests either suppressed secretion or a disrupted circadian rhythm. Most commercial lab reports do not quantify the rate of rise as a standalone number, though the raw time-series data allows a clinician to estimate it by eye or with the underlying values.

What a High Salivary Melatonin Result Means

"High" on this test can mean two different things: an earlier-than-expected DLMO (advanced phase) or a higher-than-expected peak concentration. They point to different explanations.

Advanced DLMO (Phase Advance)

A DLMO clearly earlier than 19:30 is consistent with Advanced Sleep-Wake Phase Disorder (ASWPD). People with this pattern typically feel sleepy in the early evening, fall asleep early, and wake spontaneously in the early morning. The American Academy of Sleep Medicine's International Classification of Sleep Disorders, Third Edition classifies ASWPD as a circadian rhythm sleep-wake disorder. A minority of familial cases have been linked to circadian clock gene variants (including PER2, CRY1, and CSNK1D/CK1-delta), though most ASWPD is not familial. Evening bright-light exposure is the typical first-line intervention; see below.

Elevated Peak Concentration

An unusually high salivary melatonin peak in an adult should first prompt a question about recent supplement use, since exogenous melatonin can linger in saliva. Anyone testing to assess their own endogenous rhythm should stop melatonin, and ideally other sleep aids, for at least 7 to 10 days before collection, per the lab's specific washout instructions. Outside of recent supplement use, an isolated high peak without any phase shift is uncommon and its clinical significance in adults is not well established from the sources reviewed here. In children, a markedly elevated peak that cannot be explained by supplement use warrants evaluation by a physician; this page does not have a validated numeric cutoff to offer, and any suggested threshold should be confirmed with a pediatric specialist rather than taken from this article.

What a Low Salivary Melatonin Result Means

A low result on this test can mean a delayed DLMO, a blunted peak, or both.

Delayed DLMO (Phase Delay)

A DLMO clearly later than 23:30 is the hallmark of Delayed Sleep-Wake Phase Disorder (DSWPD). A review reported an adult DSWPD prevalence estimate of about 0.17% (95% CI: 0.07 to 0.47%) based on general-population data. Adolescent prevalence is reported as substantially higher in several studies, but the specific figures vary enough by population and diagnostic method that a single adolescent percentage is not reproduced here without a directly matching source; treat any adolescent prevalence figure you see elsewhere as something to verify against its original study.

Combining morning bright-light exposure with low-dose melatonin timed several hours before the current DLMO is a commonly used approach to advance a delayed phase, with the DLMO result used to anchor the timing. Any melatonin dosing decision should be made with a treating clinician, not from this article alone.

Blunted Peak Without Phase Shift

A flat profile (peak under roughly 20 pg/mL) with a DLMO in the typical timing window suggests suppressed pineal output rather than a phase disorder. Reported contributors include:

• Beta-adrenergic blockers. A small study found that atenolol reduced nocturnal melatonin output by about 50% in hypertensive patients.
• Chronic NSAID use (ibuprofen, naproxen), which has been associated with reduced nocturnal melatonin in some studies; the size of the effect is not consistent enough across the literature to state a single reliable percentage here.
• Light exposure during sleep, including screen use overnight. Even modest light at night can suppress melatonin in some people; the specific brightness thresholds and suppression percentages reported vary by study and by individual light sensitivity.
• Alcohol. Evening alcohol intake has been associated with reduced overnight melatonin output in some studies, though the reported magnitude is not consistent enough to quote a single percentage with confidence.

Clinicians should review the full medication list before attributing a blunted profile to a primary endocrine cause.

How to Raise Low Salivary Melatonin

Raising endogenous melatonin output starts with environmental and behavioral changes before medication.

Light Management

Morning bright-light exposure helps set an earlier phase, and reducing evening blue light exposure supports the normal nighttime melatonin rise. Switching to dim, warm lighting after roughly 20:00, and reducing screen brightness or using blue-light filtering in the hours before bed, are reasonable low-risk steps. A small randomized trial found that wearing amber-tinted, blue-light-blocking glasses for two hours before bed improved sleep quality compared with clear lenses in adults with insomnia symptoms. That trial measured sleep quality outcomes rather than a specific percentage reduction in melatonin suppression, so this page does not restate a suppression percentage for blue-light glasses.

Exogenous Melatonin for Phase Correction

When behavioral changes are not enough, low physiological doses of melatonin timed several hours before the current DLMO are commonly used to advance circadian phase over several weeks. Higher doses increase total circulating melatonin and next-morning sedation risk without clearly improving phase-shifting effectiveness. The Endocrine Society's 2015 guideline discusses low-dose melatonin as the preparation used specifically for circadian phase-shifting purposes, as distinct from higher hypnotic doses used mainly for sedation. Full guideline text is available here. Exact dosing and timing should come from a clinician using the individual's own DLMO result, not a generic schedule.

Addressing Suppressant Medications

If a beta-blocker is medically necessary, switching from a non-selective agent such as atenolol or propranolol to a more cardioselective option may partially preserve nocturnal melatonin in some patients. Any medication change must go through the prescribing physician; this is not a recommendation to stop or switch a prescribed medication independently.

How to Lower High Salivary Melatonin (or Shift an Early DLMO Later)

An advanced DLMO is corrected with phase-delaying interventions, not by blocking melatonin secretion directly.

Evening Bright-Light Therapy

Evening bright-light exposure delivered a couple of hours before the current DLMO is the typical intervention for ASWPD, aimed at shifting the melatonin rise later over several weeks. Specific lux levels, session lengths, and expected shift magnitude should be set with the prescribing clinician, since protocols vary by clinic and by severity.

Chronotherapy

Progressively delaying bedtime over successive days until the desired schedule is reached is a second option, though adherence is difficult and it is generally reserved for cases where light therapy alone is insufficient.

Collecting the Test Correctly: Factors That Invalidate Results

Sample quality is the largest source of error on this test. Errors can produce false-low readings (light exposure, food or drink near a collection) or false-high readings (recent exogenous melatonin, poor sample handling).

• Maintain ambient light under 10 lux throughout the entire collection window. Even brief bright light exposure, such as a phone screen at close range, can suppress melatonin within minutes.
• Do not eat, drink anything other than water, or brush teeth for 30 minutes before each sample.
• Stop melatonin and other sleep-aid supplements for at least 7 days before collection, or longer if the lab's instructions specify a longer washout.
• Keep samples in the provided tube, freeze within 2 hours of collection if not shipping same-day, and ship on ice. Melatonin in saliva degrades over time at warmer temperatures.
• Collect at the same clock times listed in the lab's protocol regardless of how tired or alert you feel that evening. Shifting the collection schedule by even 30 minutes can distort the DLMO calculation.

A completely flat curve in a young adult with no relevant medications and good light compliance is diagnostically informative. A flat curve alongside a noted protocol deviation may simply reflect a failed collection rather than a true finding.

Who Should Order This Test

A salivary melatonin profile is generally appropriate for people with:

• Persistent difficulty falling asleep before the early morning hours despite adequate sleep opportunity (possible DSWPD)
• Inability to stay awake past the early evening with spontaneous early-morning waking (possible ASWPD)
• Shift work disorder with suspected circadian desynchrony, ideally confirmed first with actigraphy
• Autism spectrum disorder, Smith-Magenis syndrome, or another condition with a known circadian component
• A need for a pre-treatment baseline before starting exogenous melatonin, particularly in children
• Post-treatment monitoring to confirm a phase shift after several weeks of light therapy or timed melatonin

The test is less useful for insomnia driven mainly by anxiety, sleep apnea, restless legs syndrome, or sleep hygiene issues without a clear phase component. A detailed sleep history and 1 to 2 weeks of actigraphy should generally guide whether this test is worth ordering at all.

A Decision Framework: What Your Pattern Suggests and What to Check Before Acting

This is a simplified guide to reasoning through a result, not a substitute for a clinician's interpretation. Use it to know what to ask about, not to self-diagnose.

Step 1: Rule out confounders before interpreting the curve at all.

• Was ambient light kept under 10 lux the whole session? If not, the result may be a false low or a distorted curve, not a true reading.
• Was any melatonin, tryptophan, or sleep aid taken in the days before the test? If yes and the washout was shorter than instructed, treat any "high" peak as unreliable until retested.
• Was a beta-blocker or chronic NSAID in use at the time of testing? If yes, a blunted peak may reflect the medication rather than a primary circadian or pineal problem, and the next step is a medication review with the prescriber, not an immediate treatment change.

Step 2: Match the pattern to the most likely explanation.

Step 3: Know the exceptions that change the interpretation.

• Children and older adults need age-adjusted reference ranges; comparing a child's or an older adult's result to the 20-to-40-year-old adult range will misclassify a normal result as abnormal.
• A DLMO time should be compared against a person's own habitual sleep midpoint, not a population average clock time. The same DLMO can be normal for one person's schedule and a significant delay for someone with an earlier required wake time.
• Seasonal shifts of roughly half an hour in DLMO timing have been reported at higher latitudes, consistent with findings from studies on seasonal circadian phase shifts. A result taken in winter should not be compared rigidly against a summer-based reference without accounting for this.

Step 4: Next step. If the pattern and history point toward a phase disorder, the next step is a conversation with a sleep specialist about light therapy or DLMO-timed melatonin, not self-directed dosing. If the pattern points toward a medication or lifestyle suppressant, the next step is a review with the prescribing clinician before any supplement is started. If the collection protocol was not followed, the next step is a repeat test, not treatment based on an unreliable curve.

Interpreting Results in Context: Age, Sex, and Season

Melatonin secretion changes across the lifespan. Very young infants produce little melatonin, and output rises over the first months of life. Nocturnal salivary melatonin is generally much higher in young children than in adults and declines through puberty and adulthood; because the exact pediatric reference figures vary by assay and lab, this page does not restate a specific pediatric peak range as a universal number. Reference ranges should always be age-matched: comparing a child's result to the adult range, or an older adult's result to a young-adult range, will misclassify normal results as abnormal.

Sex differences in adult melatonin output appear to be modest based on available studies, and are generally not treated as clinically decisive on their own. Seasonal variation is better documented: Some researchers have found DLMO occurring somewhat earlier in winter than summer at higher latitudes, a finding relevant to seasonal mood and circadian research.

For phase-disorder diagnosis, a treating clinician should compare DLMO timing to the person's own habitual sleep midpoint rather than to a population clock-time average, since the same DLMO clock time can be normal for one schedule and a significant delay for another.